Logo Image
|Articles|March 1, 2001

Pharmaceutical Executive

  • Pharmaceutical Executive-03-01-2001
  • Volume 0
  • Issue 0

Earnings: Tough Times Ahead

Author(s)Kevin Gopal

Sodertalje, Sweden-After two consecutive years of robust postmerger growth, AstraZeneca is facing a tough 2001. The company recorded a 16 percent increase in pretax profits for 2000, but CEO Tom McKillop advises that this year}s growth will be in the 5}6 percent range when Losec/Prilosec (omeprazole)-the world}s best-selling medicine-goes off patent and the US launch of its successor Nexium (esomeprazole) is delayed.

Articles in this issue

over 25 years ago

Research: New Horizons

over 25 years ago

Outbreak: Anthrax Alarm

over 25 years ago

Patents: China on the Genome Map

over 25 years ago

Privacy, Pediatrics, and Policy

over 25 years ago

Lilly's International Family

over 25 years ago

Update: Punishment and Reprieve

over 25 years ago

Shortage: Vaccine Worries

over 25 years ago

Gateway to Japan

over 25 years ago

Surrounded

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Fayuvi
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Read more
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Addressing MFN Innovation Concerns
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Read more